Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Public ClinicalTrials.gov record NCT01393964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to assess the concentration of Elotuzumab in Myeloma patients with very low kidney function including patients on dialysis.
Study identification
- NCT ID
- NCT01393964
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- Lenalidomide Drug
- Dexamethasone Drug
- Elotuzumab (BMS-901608; HuLuc63) Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 6, 2012 (Actual)
- Primary completion
- Mar 21, 2014 (Actual)
- Completion
- Jul 18, 2016 (Actual)
- Last update posted
- Aug 3, 2017
2012 – 2016
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| Investigative Clinical Research Of Indiana, Llc | Indianapolis | Indiana | 46260 | — |
| University Of Iowa Hospitals And Clinics | Iowa City | Iowa | 52242 | — |
| University Of Maryland | Baltimore | Maryland | 21201 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Weill Cornell Medical College | New York | New York | 10021 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| Tennessee Oncology, Pllc | Nashville | Tennessee | 37203 | — |
| The University Of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| Va Puget Sound Health Care System | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01393964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 3, 2017 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01393964 live on ClinicalTrials.gov.